Eledon Pharmaceuticals (ELDN) Non-Current Deferred Tax Liability (2020 - 2026)

Eledon Pharmaceuticals (ELDN) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed 0.18% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (changed 0.18% YoY), and the FY2025 full-year result was $2.2 million, changed 0.18% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $2.2 million, roughly flat from $2.2 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $2.2 million in Q4 2025 and bottomed at $1.8 million in Q1 2022.
• The 5-year median for Non-Current Deferred Tax Liability is $1.8 million (2022), against an average of $1.9 million.
• The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability sank 51.4%; it then increased 24.6% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then climbed by 24.6% to $2.2 million in 2024, then rose by 0.18% to $2.2 million in 2025, then changed by 0.0% to $2.2 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.2 million (Q1 2026), $2.2 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.

Peer Comparison